[go: up one dir, main page]

EP0412766B1 - Fragments peptidiques du VIH - Google Patents

Fragments peptidiques du VIH Download PDF

Info

Publication number
EP0412766B1
EP0412766B1 EP90308662A EP90308662A EP0412766B1 EP 0412766 B1 EP0412766 B1 EP 0412766B1 EP 90308662 A EP90308662 A EP 90308662A EP 90308662 A EP90308662 A EP 90308662A EP 0412766 B1 EP0412766 B1 EP 0412766B1
Authority
EP
European Patent Office
Prior art keywords
peptide
cells
hiv
isoleucine
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP90308662A
Other languages
German (de)
English (en)
Other versions
EP0412766A1 (fr
Inventor
Andrew James Mcmichael
Douglas Fraser Nixon
Alain Robert Michael Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
Medical Research Council
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43806939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0412766(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Research Council, United Biomedical Inc filed Critical Medical Research Council
Priority to AT90308662T priority Critical patent/ATE103294T1/de
Publication of EP0412766A1 publication Critical patent/EP0412766A1/fr
Application granted granted Critical
Publication of EP0412766B1 publication Critical patent/EP0412766B1/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention concerns peptide fragments of HIV (human immunodeficiency virus) and the use thereof in a potential vaccine against AIDS (acquired immune deficiency syndrome), and for diagnostic and therapeutic purposes.
  • UK patent Application No. 8912651.0 (Publication No 2220939), which was published after the priority date of this application, discloses and claims, inter alia, a peptide having the amino acid sequence of a fragment of HIV which interacts specifically with a particular human leucocyte antigen (HLA) class I molecule, to stimulate cytotoxic T lymphocyte immunity.
  • HLA human leucocyte antigen
  • One such peptide specifically disclosed in the prior application has the sequence NH2-lysine-arginine -tryptophan-isoleucine-isoleucine-leucine-glycine-leucine-asparagine-lysine-isoleucine-valine-arginine-methionine-tyrosine-cysteine-COOH, which is derived from the gag (group associated antigen) p24 protein of HIV (ie one of the internal core proteins) between residues 263 and 277. This peptide is known as p24-14.
  • the carboxy-terminal cysteine is not part of the gag sequence and is added to facilitate chemical coupling reactions.
  • This peptide interacts specifically with HLA B27, and individuals with HLA B27 (about 7% of the Caucasian population) should respond to the peptide, resulting in production of cytotoxic T lymphocytes (CTL) specific for gag and HLA B27, and capable of lysing cells infected with HIV.
  • CTL cytotoxic T lymphocytes
  • the present application concerns another such peptide which has now been identified.
  • a peptide having the amino acid sequence of a fragment of HIV which interacts with a particular human leucocyte antigen (HLA) class I molcule, to stimulate cytotoxic T lymphocyte immunity the peptide having the sequence NH2-asparagine-proline-proline-isoleucine-proline-valine-glycine-glutamate-isoleucine-tyrosine-lysine-arginine-tryptophan-isoleucine-isoleucine-COOH.
  • This sequence is derived from the gag (group associated antigen) p24 protein of HIV (ie one of the internal core proteins). This peptide is known as p24-13. This peptide interacts specifically with HLA B8 and individuals with HLA B8 (about 15% of the Caucasian population) should respond to the peptide, resulting in production of cytotoxic T lymphocytes (CTL) specific for gag and HLA B8, and capable of lysing cells infected with HIV.
  • CTL cytotoxic T lymphocytes
  • virus proteins such as gag are presented to T cells as degraded peptide fragments (about 15 amino acids) bound to larger HLA class I molecules on the surface of infected cells.
  • Different peptide regions are recognised and interact specifically with different HLA class I molecules.
  • CTL will only recognise target cells that share HLA Class I molecules, ie the T cells recognise a combination of virus antigen plus self HLA.
  • HLA class I molecules There are probably about 120 different HLA class I molecules, and each individual human has a limited selection, and so will respond only to certain epitopes.
  • Epitopes recognised with different HLA can be identified and isolated in known manner or made by protein synthesis using known techniques.
  • a peptide in accordance with the invention can be used as the basis of a vaccine against AIDS, by stimulating production of CTL responsive to the relevant HLA and so priming the CTL response.
  • the present invention thus provides a vaccine against AIDS, comprising the peptide of the invention.
  • the vaccine may comprise more than one peptide, and may additionally comprise one or more peptides responsive to some of the more common HLA class I molecules to increase effectiveness.
  • the vaccine may take various different forms.
  • the vaccine may comprise a peptide or mixture of peptides for administration in solution, or absorbtion onto insoluble material or mixing with an adjuvant.
  • the peptide amino acid sequence could alternatively be used to construct synthetic or fusion proteins that contain the relevant peptide epitopes, by known recombinant DNA techniques. These proteins could be used to immunise as soluble protein or absorbed onto insoluble material or mixed wih adjuvant.
  • sequence information could be used to construct recombinant microorganisms using known techniques which would express the relevant sequences in their own proteins. Examples would be recombinant vaccinia viruses, recombinant polio myelitis viruses, recombinant BCG, recombinant salmonella, recombinant adenovirus.
  • sequence information would be to construct analogs of the peptides, or other chemicals which would interact with eg bind to the HLA molecules involved or the T cell receptors involved and interfere with or stimulate this form of immune response. Inhibition of this type of immunity might be important if this immune response plays a harmful role in any of the pathology caused by HIV. If so it may be important to regulate the levels of this type of T cell immunity in HIV seropositive individuals so as to achieve a balance between beneficial and harmful effects. Stimulation by such agents may be an alternative way of inducing an immune response in seronegative individuals.
  • a peptide in accordance with the invention can also be used for diagnostic purposes.
  • fresh peripheral blood mononuclear cells or lymphocytes obtained from biopsy material
  • lymphocytes obtained from biopsy material are prepared and added at ratios of 50:1, 25:1 and 10:1 to 104 51-chromium labelled B lymphoblastoid cells matched for the relevant HLA molecule.
  • the HLA type of patient is determined in known manner by tissue typing, and B lymphoblastoid cells obtained from a donor of known HLA type (again determined in known manner by tissue typing) amd transformed with Epstein Barr using known techniques.
  • a peptide in accordance with the invention which interacts with the relevant HLA molecule, is also added to the cells in a concentration of 10 to 100 u molar. After 4 hours incubation the supernatant is removed and the released 51-chromium measured. The 51-chromium released is compared to that released by incubation of labelled cells in detergent, which gives a maximum value, and released by labelled cells incubated in medium alone, which gives a minimum value. If lysis (defined by 51-chromium relase of at least two times the minimum value) is observed it means that there are cytotoxic T lymphocytes in the patients' mononuclear cells and these are likely to be indicative of infection with HIV.
  • Such an assay may also be useful for measurement of the patient's general immune response to HIV, and may have prognostic implications.
  • This approach may represent a very simple method which can be used for measuring cell mediated immunity in HIV seropositive patients. It may also be possible to automate the method.
  • the present invention provides a method of assaying cells for the presence of cytotoxic T lymphocytes, comprising incubating cells with labelled B lymphoblastoid cells matched for HLA type in the presence of the peptide of the invention which interacts with the relevant HLA type, and determining the amount of label released.
  • the peptide of the invention may also have potential use in therapy.
  • This and similar peptides (and other peptide epitopes that we have identified previously in our studies on influenza virus) have been used to stimulate cytotoxic T lymphocytes to grow in vitro.
  • the method involves exposing cultured peripheral blood mononuclear cells, wich contain cytotoxic T lymphocytes, to autologous cells, mononuclear cells or B lymphoblastoid cell lines, which have been treated for one hour with an appropriate peptide at approximately 10-100 ug/ml then washed in tissue culture medium and irradiated to 3000 rads.
  • the cells are then cultured in the presence of interleukin-2 at 10 units/ml.
  • cytotoxic T lymphocyte cell lines specific for the peptide have been grown, and these lines have been expanded up to 108 cells. These expanded cytotoxic T Cell lines could be used to treat patients by reinfusion.
  • cytotoxic T cell activity indicates that patients with AIDS or the AIDS related complex show low levels of cytotoxic T cell activity, whereas those who are infected with HIV but are healthy show high levels. Part of the immune deficiency syndrome therefore may be a result of impaired cytotoxic T cell activity.
  • the proposal therefore would be to reinfuse autologous cytotoxic T cells grown in vitro on synthetic peptide pulsed cells. Initially patients who had previously had a high cytotoxic T cell activity would be treated at a stage when their levels of these cells was declining. The cytotoxic T cell lines could be prepared from frozen lymphocytes taken earlier in the patient's infection.
  • the cytotoxic T cells are preferably derived from lymphocytes taken from the patient at an earlier stage.
  • the lymphocytes may be stored in frozen condition until used for preparation of the cytotoxic T cell line.
  • the peptide epitope from HIV gag p24, restricted by HLA-B27 is found to be quite well conserved between different strains of HIV 1 and HIV 2, and it was found that cytotoxic T lymphocytes from a patient infected with HIV 1 cross-reacted on the HIV 2 peptide sequence. Similar properties may apply to the peptide of the invention.
  • the peptide of the invention may be useful in vaccines to stimulate protection against both HIV 1 and HIV 2, and also for diagnostic and therapeutic purposes with patients infected with HIV 1 and/or HIV 2.
  • the peptide is derived from the gag p24 protein of HIV.
  • the carboxy-terminal cysteine is not part of the HIV gag sequence and was added to facilitate chemical coupling reactions. It may be possible later to define this peptide even more precisely.
  • cytotoxic T lymphocyte activity can be measured by killing on autologous target cells (Epstein Barr virus transformed B lymphoblastoid cell lines) that have been infected with recombinant vaccinia viruses that express single HIV proteins.
  • cytotoxic T lymphocyte response 70-80 per cent of HIV seropositive donors give a cytotoxic T lymphocyte response to the gag protein, expressed by recombinant vaccinia virus.
  • This cytotoxic T lymphocyte response is HLA restricted which means that when target cells are prepared from unrelated individuals, only those that share HLA class I antigens with the responding T cell are lysed. It has been possible to grow these cytotoxic T lymphocytes in T cell growth factor, which contains the lymphokine Interleukin-2, for up to four weeks.
  • venous blood from HIV seropositive donors was placed in heparinised containers (100ul of 100 units/ml preservative free heparin) and was diluted 2:1 with RPMI 1640 tissue culture medium (Gibco) supplemented with 100 units/ml penicillin and 200ug/ml streptamycin, in the absence of serum.
  • RPMI 1640 tissue culture medium Gibco
  • lymphocyte separation medium LSM, Flow Laboratories
  • LSM lymphocyte separation medium
  • the tube was centrifuged at room temperature at 1200 rpm for 30 minutes after which time peripheral blood mononuclear cells (PBMC) were removed from the interface.
  • PBMC peripheral blood mononuclear cells
  • the PBMC were washed twice with RPMI-1640 then resuspended in 8ml RPMI 1640 + 10% foetal calf serum ("R10”) and counted.
  • R10 foetal calf serum
  • 1/8th of the PBMC were incubated in 50 ml flasks (Falcon) with added R10 to a concentration of 1.5 x 106 cells/ml.
  • Phytohaemagglutinin (PHA - Wellcome Diagnostics) was added at 1/200 final concentration (2ug/ml). These cells were incubated at 37°C in 5% CO2 in air for 24 hours. The remaining 7/8th of the PBMC were cultured at a concentration of 1.5 x 106/ml in R10 at 37°C in 5% CO2/air in a 50ml tissue culture flask.
  • the PHA stimulated cells were washed twice in R10, resuspended in R10 at 1.0 x 106/ml and added to the unstimulated cells.
  • the cultures were left in the incubator for seven days prior to use in the cytotoxic T cell assay.
  • T cell growth factor (Lymphocult T; Biotest) was added to the culture at 10 units/ml and the growing cells were kept at 0.5-1 x 106/ml, being fed with R-10 plus 10u/ml T cell growth factor every 3 days.
  • Epstein Barr virus transformed B lymphoblastoid cell lines autologous matched or mismatched at HLA class I were washed and resuspended to 1-5 x 106/100ul in R10. 300uCi Na2 51CrO4 (Cr51 Amersham) was added and the cells incubated for one hour at 37°C in 5% CO2-air. The cells were washed once and then resuspended in peptide solutions (peptide stock dissolved in R10 at 1mg/ml) at a final concentration of 10ug/ml. Each peptide was tested separately.
  • the autologous B lymphoblastoid cell lines were either uninfected and not peptide treated (negative control) or infected with recombinant vaccinia virus (10pfu/cell for 4 hours at 37°C in 5% CO2 in air) (positive control) (McMichael et al, J.Gen.Virol 67:719, 1986).
  • Cells were harvested by centrifuging at 1500 rpm for 5 minutes and resuspended in R10 for use in the CTL assay.
  • Target cells were dispensed at 104 cells/well in 96 well round bottomed micro-titre trays in 50ul R10 and effector cells were added in 100ul of the same medium.
  • Spontaneous 51Cr release by target cells in medium alone varied between 8% - 30% of count released by triton X100.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (7)

  1. Peptide ayant la séquence d'acides aminés d'un fragment de HIV qui interagit avec une molécule particulière de classe I d'un antigène de leucocyte humain (HLA), pour stimuler l'immunité d'un lymphocyte cytotoxique T, le peptide ayant la séquence NH₂-asparagine-proline-proline-isoleucine-proline-valine-glycine-glutamate-isoleucine-tyrosine-lysine-arginine-tryptophane-isoleucine-isoleucine-COOH.
  2. Vaccin contre le sida, comprenant un peptide selon la revendications 1.
  3. Vaccin selon la revendication 2 comprenant plus d'un peptide, chaque peptide étant sensible à une molecule HLA de classe I différente.
  4. Vaccin selon la revendication 2 ou 3, comprenant un peptide ou un mélange de peptides pour l'administration en solution, ou sous forme absorbée sur un matériau insoluble ou mélangé à un adjuvant.
  5. Vaccin selon la revendication 2 ou la revendication 3, comprenant une protéine synthétique ou de fusion qui contient le (les) épitope(s) pertinent(s) du peptide, pour l'administration en solution, ou sous forme absorbée sur un matériau insoluble ou mélangé avec un adjuvant.
  6. Vaccin selon la revendication 2 ou la revendication 3, comprenant un microorganisme recombinant construit pour exprimer la(les) séquence(s) peptidique(s) pertinente(s) comprenant un peptide selon la revendication 1.
  7. Méthode pour tester la présence de cellules de type lymphocytes cytotoxiques T, comprenant l'incubation des cellules avec des cellules lymphoblastoïdes B marquées, correspondant à un type HLA en présence d'un peptide selon la revendication 1 ou la revendication 2, qui interagit avec le type de HLA pertinent, et la détermination de la quantité de marqueur libéré.
EP90308662A 1989-08-09 1990-08-07 Fragments peptidiques du VIH Revoked EP0412766B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT90308662T ATE103294T1 (de) 1989-08-09 1990-08-07 Peptidfragmente von hiv.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8918200 1989-08-09
GB898918200A GB8918200D0 (en) 1989-08-09 1989-08-09 The peptide fragments of hiv

Publications (2)

Publication Number Publication Date
EP0412766A1 EP0412766A1 (fr) 1991-02-13
EP0412766B1 true EP0412766B1 (fr) 1994-03-23

Family

ID=43806939

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90308662A Revoked EP0412766B1 (fr) 1989-08-09 1990-08-07 Fragments peptidiques du VIH

Country Status (12)

Country Link
US (1) US5700635A (fr)
EP (1) EP0412766B1 (fr)
JP (1) JPH04507100A (fr)
AT (1) ATE103294T1 (fr)
CA (1) CA2064691A1 (fr)
DE (1) DE69007571T2 (fr)
DK (1) DK0412766T3 (fr)
ES (1) ES2054256T3 (fr)
GB (2) GB8918200D0 (fr)
HK (1) HK141494A (fr)
SG (1) SG130094G (fr)
WO (1) WO1991001996A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
DE68925660T2 (de) * 1988-06-10 1996-09-26 United Biomedical Inc Peptidfragmente von HIV
EP0510054A1 (fr) * 1990-01-05 1992-10-28 United Biomedical, Inc. Fragments de la proteine du noyau de vih-1
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
KR100235849B1 (ko) * 1993-10-19 1999-12-15 에가시라 구니오 HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS)
GB9426153D0 (en) * 1994-12-23 1995-02-22 Medical Res Council Improvements in or relating to vaccines
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
WO2009132222A2 (fr) * 2008-04-24 2009-10-29 Avery Dennison Corporation Feuille comprenant des étiquettes amovibles et procédé connexe
EP2620446A1 (fr) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogènes pour la vaccination contre le VIH
BR112022009421A2 (pt) 2019-11-14 2022-10-25 Aelix Therapeutics S L Regimes de dosagem para vacinas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6713287A (en) * 1986-01-06 1987-07-09 F. Hoffmann-La Roche & Co. Expression of htlv-iii gag-gene
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
EP0330359A3 (fr) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I

Also Published As

Publication number Publication date
ATE103294T1 (de) 1994-04-15
GB2250994A (en) 1992-06-24
US5700635A (en) 1997-12-23
GB2250994B (en) 1993-08-25
JPH04507100A (ja) 1992-12-10
CA2064691A1 (fr) 1991-02-10
GB9201468D0 (en) 1992-04-01
DE69007571D1 (de) 1994-04-28
DE69007571T2 (de) 1994-09-08
EP0412766A1 (fr) 1991-02-13
DK0412766T3 (da) 1994-07-18
WO1991001996A1 (fr) 1991-02-21
GB8918200D0 (en) 1989-09-20
HK141494A (en) 1994-12-23
ES2054256T3 (es) 1994-08-01
SG130094G (en) 1995-01-13

Similar Documents

Publication Publication Date Title
US5700469A (en) HIV-1 core protein fragments
Takahashi et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.
US5459238A (en) Peptide fragments of HIV
Macatonia et al. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells
Pialoux et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
Hadida et al. Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis.
Sipsas et al. Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1.
EP0412766B1 (fr) Fragments peptidiques du VIH
EP0584348A1 (fr) Vaccin genetique pour virus d'immunodefience
KR20190104586A (ko) 예비-면역화 단계가 없는 hiv 면역요법
EP0400076B1 (fr) Antigene synthetique suscitant une reaction anti-vih
AU649502B2 (en) Molecular clones of HIV-1 and uses thereof
Nardelli et al. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide
Montefiori et al. Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus
Manca et al. Dendritic cells are potent antigen-presenting cells for in vitro induction of primary human CD4+ T-cell lines specific for HIV gp120
Devare et al. Genomic diversity of the acquired immunodeficiency syndrome retroviruses is reflected in alteration of its translational products.
EP0260714B1 (fr) Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA
WO1998059074A1 (fr) Virus de l'immunodeficience humaine induisant le sida chez un primate non humain
KENT et al. Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses
CA2158461A1 (fr) Stimulation de la reponse immunitaire par une proteine virale
GB2273709A (en) Peptide fragments of HIV
Gorse et al. Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein
Miyoshi Biology of T-cell leukemia virus: Search for an animal system
Lea Cell-mediated immune response to equine infectious anemia virus
Zhou Expression and immunogenicity of DNA vaccines containing the env and gag-pol genes of equine infectious anemia virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19910228

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDICAL RESEARCH COUNCIL

17Q First examination report despatched

Effective date: 19921005

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 103294

Country of ref document: AT

Date of ref document: 19940415

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69007571

Country of ref document: DE

Date of ref document: 19940428

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GR IT LI LU NL SE

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: UNITED BIOMEDICAL INC.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2054256

Country of ref document: ES

Kind code of ref document: T3

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: UNITED BIOMEDICAL, INC.

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3012272

EPTA Lu: last paid annual fee
NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: UNITED BIOMEDICAL, INC. TE HAUPPAUGE, NEW YORK, VE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

NLS Nl: assignments of ep-patents

Owner name: UNITED BIOMEDICAL, INC. TE HAUPPAUGE, NEW YORK, VE

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

EAL Se: european patent in force in sweden

Ref document number: 90308662.7

26 Opposition filed

Opponent name: CONNAUGHT LABORATORIES LIMITED

Effective date: 19941223

R26 Opposition filed (corrected)

Opponent name: CONNAUGHT LABORATORIES LIMITED

Effective date: 19941223

NLR1 Nl: opposition has been filed with the epo

Opponent name: CONNAUGHT LABORATORIES LIMITED

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19950628

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19950701

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19950721

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19950802

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19950811

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19950816

Year of fee payment: 6

ET1 Fr: translation filed ** revision of the translation of the patent or the claims
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19960724

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960807

Ref country code: DK

Effective date: 19960807

Ref country code: AT

Effective date: 19960807

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960808

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960808

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19960830

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19960923

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19961203

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19970228

REG Reference to a national code

Ref country code: GR

Ref legal event code: MM2A

Free format text: 3012272

RDAH Patent revoked

Free format text: ORIGINAL CODE: EPIDOS REVO

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed

Ref document number: 90308662.7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19970703

Year of fee payment: 8

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 19970504

NLR2 Nl: decision of opposition